Company Filing History:
Years Active: 2019
Title: Innovator Cheng-Wei Chang: Pioneering Advancements in Sustained Release Medication
Introduction: Cheng-Wei Chang is a notable inventor based in Tainan, Taiwan, recognized for his impactful contribution to pharmaceutical innovations. With a focus on enhancing medication delivery systems, Chang has made significant strides in the field of drug formulation, particularly with his patented invention.
Latest Patents: Cheng-Wei Chang holds a patent for a "Sustained release oral dosage form containing dalfampridine." This innovative formulation allows for the administration of dalfampridine once daily, providing a more manageable dosing regimen for patients. The sustained release oral dosage form includes dalfampridine as the active pharmaceutical ingredient, along with osmotic agents incorporated into the tablet core. This design effectively minimizes adverse effects, helps prevent alcohol-induced dose dumping, and ensures a consistent drug release rate to maintain adequate plasma concentration levels.
Career Highlights: Currently, Cheng-Wei Chang is associated with Pharmadax Inc., where his expertise in pharmaceutical innovations is leveraged to improve patient outcomes. His work highlights a commitment to developing effective medication solutions, emphasizing both efficacy and patient safety.
Collaborations: Cheng-Wei Chang works alongside talented colleagues, including Chih-Yao Yang and Jen-Sen Wu. Their collaborative efforts play a crucial role in driving forward the mission of Pharmadax Inc. to deliver high-quality pharmaceutical products.
Conclusion: Cheng-Wei Chang exemplifies the spirit of innovation within the pharmaceutical industry. Through his patented work on sustained release oral dosage forms, he has made a significant impact on how medications are delivered. As a vital member of Pharmadax Inc., Chang continues to contribute to advances in drug formulation, ultimately working towards better health outcomes for patients.